Loading
A phase 1/2 trial of EB103 in non-Hodgkin lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma, run by Estrella Biopharma, Inc., now recruiting.
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT06343311 by Estrella Biopharma, Inc., with 21 participants planned, started 2024-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: EB103.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/